Patents by Inventor Seigo Sawada
Seigo Sawada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9174979Abstract: A novel compound having an excellent NF?B inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom; R2 represents a hydroxyl group, or a lower alkyloxy group; R3 represents a hydrogen atom, a lower alkyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R1, R3, R4 and R7 aType: GrantFiled: October 23, 2009Date of Patent: November 3, 2015Assignee: KABUSHIKI KAISHA YAKULT HONSHAInventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
-
Patent number: 8569327Abstract: A novel compound having an excellent NF?B inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.Type: GrantFiled: October 23, 2009Date of Patent: October 29, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
-
Patent number: 8501813Abstract: It is intended to provide a novel compound that has an excellent ?-secretase inhibitory effect and specifically inhibits A? production. The present invention provides a compound of the following formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a linear or branched alkyl group having 1 to 4 carbon atoms or a phenyl group; R2 represents a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted by one or more phenyl or halogenophenyl groups; R3 represents a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted by one or more hydroxyl groups; R4 represents a linear or branched alkyl group having 1 to 4 carbon atoms; and the symbol “*” represents a chiral center.Type: GrantFiled: July 1, 2008Date of Patent: August 6, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Atsuhiro Abe, Hideaki Shimizu, Seigo Sawada, Hiroshi Kodaira
-
Patent number: 8476438Abstract: Disclosed is a process for production of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin from a camptothecin composition containing 18,19-dehydrocamptothecin without producing any vinyl form of the compound. The process is characterized by catalytically reducing at least one compound selected from a compound (1) and others in the process of producing a compound (5) from a composition containing the compound (1).Type: GrantFiled: April 27, 2007Date of Patent: July 2, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Seigo Sawada, Takashi Yaegashi
-
Patent number: 8466287Abstract: In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresponds to a CDE ring moiety of a camptothecin (CPT) skeleton.Type: GrantFiled: October 21, 2011Date of Patent: June 18, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Hiroyuki Nishiyama, Seigo Sawada
-
Patent number: 8351440Abstract: An IP address and a MAC address of each of communication devices connected to a plurality of communication ports provided in a switching hub device are associated in an ARP table. Also, priority information representing the communication priority of each communication device is received, and the received priority information is associated with the MAC address of the communication device. When no IP address of a transmission source included in a data packet received at each communication port exists in the ARP table, the IP address and the MAC address of the transmission source are added to the ARP table and priority information is attached to the ARP table.Type: GrantFiled: September 19, 2008Date of Patent: January 8, 2013Assignee: Fujitsu LimitedInventors: Seigo Sawada, Takumi Iwai, Yoshinari Oshio, Takao Nakamura, Tsuneyuki Takai
-
Publication number: 20120142926Abstract: Disclosed is a process for production of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin from a camptothecin composition containing 18,19-dehydrocamptothecin without producing any vinyl form of the compound. The process is characterized by catalytically reducing at least one compound selected from a compound (1) and others in the process of producing a compound (5) from a composition containing the compound (1).Type: ApplicationFiled: April 27, 2007Publication date: June 7, 2012Applicant: Kabushiki Kaisha Yakult HonshaInventors: Seigo Sawada, Takashi Yaegashi
-
Publication number: 20120041204Abstract: In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresponds to a CDE ring moiety of a camptothecin (CPT) skeleton.Type: ApplicationFiled: October 21, 2011Publication date: February 16, 2012Applicant: Kabushiki Kaisha Yakult HonshaInventors: Hiroyuki Nishiyama, Seigo Sawada
-
Patent number: 8067595Abstract: In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresponds to a CDE ring moiety of a camptothecin (CPT) skeleton.Type: GrantFiled: June 8, 2006Date of Patent: November 29, 2011Assignee: Kabushiki Kaisha Yakult HonshaInventors: Hiroyuki Nishiyama, Seigo Sawada
-
Publication number: 20110201638Abstract: A novel compound having an excellent NF?B inhibitory effect is provided and specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, a lower alkyloxy group, or a halogen atom; R2 represents a hydroxyl group, or a lower alkyloxy group; R3 represents a hydrogen atom, a lower alkyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, or a lower alkylcarbonyloxy group (excluding the case where R1, R3, R4 and R7Type: ApplicationFiled: October 23, 2009Publication date: August 18, 2011Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
-
Publication number: 20110201637Abstract: A novel compound having an excellent NF?B inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.Type: ApplicationFiled: October 23, 2009Publication date: August 18, 2011Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
-
Publication number: 20110071224Abstract: It is intended to provide a novel compound that has an excellent ?-secretase inhibitory effect and specifically inhibits A? production. The present invention provides a compound of the following formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a linear or branched alkyl group having 1 to 4 carbon atoms or a phenyl group; R2 represents a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted by one or more phenyl or halogenophenyl groups; R3 represents a linear or branched alkyl group having 1 to 4 carbon atoms which may be substituted by one or more hydroxyl groups; R4 represents a linear or branched alkyl group having 1 to 4 carbon atoms; and the symbol “*” represents a chiral center.Type: ApplicationFiled: July 1, 2008Publication date: March 24, 2011Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Atsuhiro Abe, Hideaki Shimizu, Seigo Sawada, Hiroshi Kodaira
-
Patent number: 7897772Abstract: The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, citric acid, maleic acid, and succinic acid to irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.Type: GrantFiled: September 29, 2005Date of Patent: March 1, 2011Assignee: Kabushiki Kaisha Yakult HonshaInventors: Hideaki Shimizu, Miyuki Uchida, Seigo Sawada, Norimasa Kaneda, Tsuneo Matsumoto
-
Patent number: 7846473Abstract: Provided is an irinotecan formulation capable of supporting irinotecan and/or a salt thereof in a closed vesicle carrier at a high concentration and existing in blood for a long period of time by dramatically improved retentivity in blood compared to a conventionally known irinotecan liposome formulation. That is, an irinotecan formulation including a closed vesicle formed by a lipid membrane, in which irinotecan and/or a salt thereof is encapsulated at a concentration of at least 0.07 mol/mol (drug mol/membrane total lipid mol). There is an ion gradient between an inner aqueous phase and an outer aqueous phase in the irinotecan formulation. The closed vesicle is preferably liposome, in which only the outer surface of the liposome is preferably modified with a surface-modifying agent containing a hydrophilic polymer.Type: GrantFiled: May 31, 2005Date of Patent: December 7, 2010Assignees: Terumo Kabushiki Kaisha, Kabushiki Kaisha Yakult HonshaInventors: Keisuke Yoshino, Shigenori Nozawa, Masashi Isozaki, Seigo Sawada, Ikuo Kato, Takeshi Matsuzaki
-
Publication number: 20090080447Abstract: An IP address and a MAC address of each of communication devices connected to a plurality of communication ports provided in a switching hub device are associated in an ARP table. Also, priority information representing the communication priority of each communication device is received, and the received priority information is associated with the MAC address of the communication device. When no IP address of a transmission source included in a data packet received at each communication port exists in the ARP table, the IP address and the MAC address of the transmission source are added to the ARP table and priority information is attached to the ARP table.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Inventors: Seigo SAWADA, Takumi Iwai, Yoshinari Oshio, Takao Nakamura, Tsuneyuki Takai
-
Patent number: 7488825Abstract: A method for preparing a novel crystalline polymorphic irinotecan hydrochloride which is excellent in the solubility in water and reduced in the content of impurities is provided. A method for preparing c-type crystals of irinotecan hydrochloride having diffraction peaks (2?) at 9.15°, 10.00°, 11.80°, 12.20°, 13.00° and 13.40° in the powder X-ray diffractometry characterized by mixing irinotecan with one or more solvents selected from the group consisting of acetone, acetonitrile and tetrahydrofuran, adding hydrochloric acid, and collecting the formed crystals.Type: GrantFiled: February 24, 2004Date of Patent: February 10, 2009Assignee: Kabushiki Kaisha Yakult HonshaInventors: Hideaki Shimizu, Atsuhiro Abe, Takashi Yaegashi, Seigo Sawada
-
Publication number: 20090023927Abstract: In order to efficiently supply CPT, which is a starting compound of irinotecan hydrochloride and a variety of camptothecin derivatives, by a practical total synthesis, the invention provides a means of efficiently preparing a tricyclic ketone that corresponds to a CDE ring moiety of a camptothecin (CPT) skeleton.Type: ApplicationFiled: June 8, 2006Publication date: January 22, 2009Applicant: Kabushiki Kaisha Yakult HonshaInventors: Hiroyuki Nishiyama, Seigo Sawada
-
Patent number: 7378555Abstract: The present invention is to prepare efficiently 2?-amino-5?-hydroxypropiophenone corresponding to the AB-ring part of camptothecin (CPT) skeleton and a tricyclic ketone corresponding to the CDE-ring part in order to provide efficiently CPT by the total synthesis, which is a starting material for irinotecan hydrochloride and various kinds of camptothecin derivatives, and to provide stably CPT and its derivatives.Type: GrantFiled: September 8, 2006Date of Patent: May 27, 2008Assignee: Kabushiki Kaisha Yakult HonshaInventors: Takanori Ogawa, Hiroyuki Nishiyama, Miyuki Uchida, Seigo Sawada
-
Publication number: 20080069868Abstract: Provided is an irinotecan formulation capable of supporting irinotecan and/or a salt thereof in a closed vesicle carrier at a high concentration and existing in blood for a long period of time by dramatically improved retentivity in blood compared to a conventionally known irinotecan liposome formulation. That is, an irinotecan formulation including a closed vesicle formed by a lipid membrane, in which irinotecan and/or a salt thereof is encapsulated at a concentration of at least 0.07 mol/mol (drug mol/membrane total lipid mol). There is an ion gradient between an inner aqueous phase and an outer aqueous phase in the irinotecan formulation. The closed vesicle is preferably liposome, in which only the outer surface of the liposome is preferably modified with a surface-modifying agent containing a hydrophilic polymer.Type: ApplicationFiled: May 31, 2005Publication date: March 20, 2008Applicants: TERUMO KABUSHIKI KAISHA, KABUSHIKI KAISHA YAKULT HONSHAInventors: Keisuke Yoshino, Shigenori Nozawa, Masashi Isozaki, Seigo Sawada, Ikuo Kato, Takeshi Matsuzaki
-
Publication number: 20070299099Abstract: The present invention is directed to an irinotecan acid addition salt which is formed through addition of an acid selected from the group consisting of sulfuric acid, nitric acid phosphoric acid, methanesulfonic acid, citric acid maleic acid and succinic acid to Irinotecan, to a method for producing the salt, and to a pharmaceutical composition containing the salt. The addition salt requires no heating process during drug preparation and provides an aqueous drug product in which the salt is stably dissolved.Type: ApplicationFiled: September 29, 2005Publication date: December 27, 2007Applicant: KABUSHIKI KAISHA YAKULT HONSHAInventors: Hideaki Shimizu, Miyuki Uchida, Seigo Sawada, Norimasa Kaneda, Tsuneo Matsumoto